Search results: (10000)
News Brain Metastases Are Not an Absolute Contraindication for Antiplatelet Therapy
On one hand, there's a higher risk of thromboembolic events, and on the other, a higher risk of intracranial bleeding. Prophylactic and therapeutic interventions for blood clotting are necessary for cancer patients in indicated cases. But what about the risk of bleeding in patients with CNS malignancies?
News Long-term effect of the triple combination of perindopril, indapamide, and amlodipine on left ventricular hypertrophy in hypertension
A recent open-label interventional study aimed to describe the long-term effect of a fixed triple combination of perindopril, indapamide, and amlodipine compared to a free combination of a RAAS inhibitor, diuretic, and calcium channel blocker on the reduction of left ventricular hypertrophy (LVH) in hypertensive outpatients.
News How and with What the National Registry of Primary Immunodeficiencies Benefits Specialists and Patients
Primary immunodeficiencies constitute a very heterogeneous group of congenital diseases. They affect both specific and nonspecific immunity and are classified accordingly. The care for patients with antibody production disorders and hereditary angioedema (HAE) is economically the most demanding and relatively specific. Can a specialized registry help improve this care?
News Can Antihypertensives Reduce the Risk of Dementia? The Answer Suggests the Angiotensin Hypothesis and a Post-Hoc Analysis of an Observational Study
The use of antihypertensives that do not reduce angiotensin II levels, such as angiotensin receptor blockers (ARBs, i.e., sartans) and calcium channel blockers (CCBs), has been associated with a lower risk of dementia in studies. In the research cited below, the authors aimed to determine whether this effect persists longer than the follow-up period in previous studies.
News Targeted Treatment and Quality of Life in Patients with Follicular Lymphoma
The GALLIUM clinical trial evaluated chemotherapy in combination with targeted treatment using rituximab or obinutuzumab in previously untreated patients with advanced follicular lymphoma (FL). A secondary aim of the study was to assess the health-related quality of life. The results of the analysis were recently published in the journal Annals of Hematology.
News Can Artificial Intelligence Help Personalize Treatment for Cardiology Patients?
According to data from the World Health Organization (WHO), cardiovascular diseases (CVDs) claim an estimated 17.9 million lives annually worldwide, making them the leading cause of death. More than 4 out of 5 of these deaths are due to heart attacks and strokes, and one-third occur in people under the age of 70. An innovative project called NextGen will newly address cardiovascular diseases. Its goal is to use artificial intelligence (AI) and patient health information and genetic profiles to personalize their treatment. The project received 7.6 million euros from the EU program Horizon Europe and will be led by a 21-member consortium including representatives from the European Society of Cardiology (ESC).
News INTERACTIVE CASE STUDY: Treatment of glaucoma medications without preservatives – current trend
The use of glaucoma medications without preservatives has been a trend in recent years. You can try their clinical application in the role of a prescribing doctor in an interactive case study. Practical information about this popular local treatment is based on the evidence-based medicine foundation, provided by its author MUDr. Petr Výborný, CSc., from the Eye Clinic of the 1st Faculty of Medicine, Charles University and University Military Hospital in Prague.
News Treatment of Schizophrenia in a Patient at Risk of Developing Metabolic Syndrome – Interactive Case Study
A 34-year-old man has been under psychiatric care for 3 years due to a psychotic disorder. Three years ago, he had his first short hospitalization due to marked paranoid symptoms: feelings of being watched, eavesdropping, auditory hallucinations of an imperative nature...
News Tofacitinib Helps Restore Intestinal Epithelial Barrier
The Janus kinase inhibitor (JAKi) tofacitinib was relatively recently approved for the treatment of ulcerative colitis, but its effect on the intestinal epithelium remains a subject of research. The objective of the study presented below was to determine how tofacitinib aids in the repair of the cytokine-damaged intestinal epithelial cell barrier.
News Currently on the Issue of Interchangeability of Preparations with Levothyroxine in Practice
Levothyroxine (LT4) in oral form is the standard therapy for patients with hypothyroidism. Given the legislative possibility of generic substitution and the number of original and generic preparations containing LT4, its substitution is possible, though not recommended. What are the practical conclusions?
News Limosilactobacillus reuteri as a supplement for improving periodontal health when oral hygiene is compromised
The effect of probiotics on periodontal health was investigated in a German study conducted on a group of sailors during their service at sea. Among the most common causes of the overgrowth of virulent pro-inflammatory microorganisms in the oral microbiota is impaired oral hygiene, which is significantly hindered in the conditions of a naval mission.
News Can tofacitinib have a positive impact on the mental stress of patients with rheumatoid arthritis?
In the population of patients with rheumatoid arthritis (RA), there is a higher incidence of depression and anxiety compared to the healthy population. These psychiatric comorbidities can lead to a reduced quality of life and a poorer response to treatment. The aim of the post-hoc analysis presented below was to monitor the effect of tofacitinib on improving anxiety and depression in patients with RA.
News With MD Eva Drbohlavová on Innovations in the Treatment of von Willebrand Disease and Improving Patients' Quality of Life
Von Willebrand Disease (vWD), as the most common congenital bleeding disorder, remains underdiagnosed. However, thanks to new insights and advances in genetic testing, both diagnosis and long-term prophylaxis of the disease are gradually improving, leading to a significant reduction in bleeding and better quality of life for patients. We discuss this in more detail with MD Eva Drbohlavová from the Department of Clinical Hematology at the Regional Hospital Liberec.
News How Does the Long-Term Effect of Beta Blocker Use Affect Clinical Outcomes in Patients After Myocardial Infarction?
In patients after myocardial infarction (MI), beta blockers (BB) still hold an important place in secondary prevention according to recommended procedures. However, the question could be their long-term effect on clinical outcomes, as different results can be found in the literature – this fact led the authors of the work cited below to perform a systematic review and meta-analysis of studies dedicated to this issue.
News Three tests to confirm the diagnosis of acquired hemophilia – infographic
Acquired hemophilia (AHA) typically manifests with spontaneous bleeding in patients with no prior personal history of significant bleeding.1–4 The cause of the bleeding is a significant decrease in FVIII activity induced by autoantibodies against coagulation factor VIII.5 In polymorbid patients, established antithrombotic therapy at the time of AHA diagnosis may also contribute to the bleeding.4
News Do Asthma Bronchiale and COPD Represent a Risk Factor for Severe COVID-19 and Death?
It is well known that patients with bronchial asthma and chronic obstructive pulmonary disease (COPD) have a higher risk of severe course of common viral respiratory diseases. A study by Belgian authors involving several hundred individuals evaluated the risk of ICU admission and death due to COVID-19 in patients with asthma and COPD compared to patients without these conditions. The other goal was to determine whether these risks are influenced by inhalation corticosteroid therapy or not.
News Cardiovascular Interventions with Continued Therapy with Dabigatran − Insights from the GLORIA-AF Study
An analysis using data from an international registry of patients with newly diagnosed atrial fibrillation evaluated the safety and efficacy of continued therapy with dabigatran during cardioversion or atrial fibrillation ablation, pacemaker implantation, and coronary angiography with possible stent implantation.
News Probiotic L. reuteri in combination with vitamin D3 and krill oil suppresses experimental intestinal inflammation
Previous placebo-controlled studies have shown that oral administration of a probiotic containing Lactobacillus reuteri is associated with a significant increase in plasma levels of 25-hydroxyvitamin D. According to a recent experimental work, the combination of this probiotic with vitamin D3 and krill oil leads to the suppression of intestinal mucosal inflammation.
News Update of the Blue Book: What's New in the Treatment of Metastatic NSCLC with an ALK Gene Mutation?
As of March 1, 2022, the 28th update of the Blue Book by the Czech Society for Oncology of ČLS JEP was released. Let's take a look at what changes it has brought compared to the previous version in the treatment of metastatic non-small cell lung cancer (NSCLC) with a driver mutation in the ALK gene.
News Can Empagliflozin Also Act Against Gout?
Gliflozins, or sodium-glucose cotransporter 2 inhibitors (SGLT2i), are not only effective antidiabetic agents but also exhibit cardio- and renoprotective effects. It now appears that in type 2 diabetics, they may lower serum uric acid levels and help prevent the development of gout. This was suggested by a post hoc analysis of data from the EMPA-REG OUTCOME study in the case of empagliflozin.
News Effect of Prostaglandin Analogues With and Without Preservatives on Meibomian Glands in Glaucoma Patients
Prostaglandin analogues (PGA) have become a standard in the treatment of open-angle glaucoma. However, their long-term use may be associated with eye irritation or damage to the Meibomian glands. The study presented below aimed to determine whether these changes are directly caused by PGAs or the preservatives in the eye drops.
News Treatment of Glaucoma: Without Preservatives for Everyone?
A comprehensive report by Professor John Thygesen from the University Hospital in Copenhagen analyzes patient groups for whom preservative-free antiglaucoma medications are particularly suitable. In conclusion, he suggests that if there are no price differences, widespread treatment with preservative-free preparations is preferable.